Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Jan 9, 2023
- Accession no.
- 0001415889-23-000709
- Filed
- Jan 9, 2023
- Trade date
- Jan 6, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market sales total $267.2K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2023 | Common Stock | MOption exerciseAcquired | +2,413 | $1.74 | +$4,198.62 | 2,413 | Direct | |
| Jan 6, 2023 | Common Stock | MOption exerciseAcquired | +7,871 | $2.14 | +$16,843.94 | 10,284 | Direct | |
| Jan 6, 2023 | Common Stock | SSaleDisposed | −7,492 | $25.62F2 | −$191,945.04 | 2,792 | Direct | |
| Jan 6, 2023 | Common Stock | SSaleDisposed | −2,792 | $26.95F3 | −$75,244.4 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2023 | Common Stock | MOption exerciseDisposed | −906 | $0.00 | $0 | 10,866 | Direct | |
| Jan 6, 2023 | Common Stock | MOption exerciseDisposed | −1,507 | $0.00 | $0 | 28,629 | Direct | |
| Jan 6, 2023 | Common Stock | MOption exerciseDisposed | −1,018 | $0.00 | $0 | 27,497 | Direct | |
| Jan 6, 2023 | Common Stock | MOption exerciseDisposed | −6,853 | $0.00 | $0 | 198,724 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.36 to $26.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.48 to $27.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary